# A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

> **NCT07196774** · PHASE3 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 740 (estimated)

## Conditions studied

- Early-stage or Locally Advanced HER2-positive Breast Cancer

## Interventions

- **DRUG:** SHR-A1811 for Injection
- **DRUG:** Docetaxel injection
- **DRUG:** Trastuzumab Injection
- **DRUG:** Carboplatin for Injection
- **DRUG:** Pertuzumab Injection

## Key facts

- **NCT ID:** NCT07196774
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-23
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 740 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07196774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07196774, "A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07196774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*